When does the mounjaro patent expire?

When does the Mounjaro (tirzepatide) patent expire?

Mounjaro is manufactured and marketed by Eli Lilly. The next key date people look for is when the underlying patents covering tirzepatide lose legal protection and generic or biosimilar competitors can enter without infringement risk. Patent expiration timing for Mounjaro depends on the specific patent(s) in force, which can vary by country and claim scope.

DrugPatentWatch.com tracks these patent timelines for tirzepatide/Mounjaro and is a practical place to check the specific expiration dates for the relevant patents listed there: DrugPatentWatch.com – Mounjaro (tirzepatide) patents and exclusivity. [1]

Why the “patent expiry” date can differ from when generics show up

Even after patents expire, competitors may still face other legal barriers such as:
- Additional, later-expiring patents that still block full generic market entry.
- Regulatory exclusivities tied to approval and formulation changes.
- Litigation that can delay launch even after an expiration date is reached.

Because of this, the date shown for one patent may not be the date a generic version appears in the market.

What to check if you need the exact date for your use case

If you’re trying to pinpoint when generics could realistically enter, look at:
- The specific jurisdiction (U.S. vs. EU vs. other markets).
- Whether you care about the first patent expiry date or the last listed blocking patent.
- Whether the timeline includes “patent expiration” versus “exclusivity” (a related but separate concept).

DrugPatentWatch.com’s listing of Mounjaro’s patent estate is the best match to those needs because it compiles the individual patents that can drive the timeline. [1]

Source

1. DrugPatentWatch.com – Mounjaro (tirzepatide) patents and exclusivity